FIRST CLICK HERE AND READ OUR OVERVIEW
The UK’s National Institute for Clinical Excellence (NICE) has added PLDH to the approved topotecan, as a second line drug for use with advanced ovarian cancers.
NICE have suggested that PLDH has a simpler administration schedule.